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Summary 
The human immunoddiciency, type II bare lymphocyte syndrome (BLS), has been attributed 
to a defect in the transcription of class II histocompatibility  genes. Immunocompetence~  as assessed 
by functional exogenous antigen presentation, was not restored in immortalized B cells, derived 
from a BLS patient, after transfection with HLA-DR class II structural genes.  Incubation of 
protein antigens, as well as infectious virus, with DR-transfected BLS cells failed to induce activation 
of antigen-specific  helper T lymphocytes. Peptide antigens were presented by class II molecules 
displayed on BLS cells, although the conformation of these class II proteins was altered as indicated 
by epitope mapping. This defect in antigen presentation was independent of the specific class 
II DR allele transfected into BLS cells. Genetic complementation analysis has been used with 
BLS cells to demonstrate that the defect in class II gene transcription is linked to the absence 
of a tram-acting factor. Similarly, functional class II dimers were restored after in vitro fusion 
of cells derived from two distinct BLS complementation  groups, implying that specific  transcriptional 
control elements are shared by a gene critical for antigen presentation and genes encoding HLA 
class II antigens. Thus, two important functionally linked pathways of class II molecules, structural 
gene expression and antigen presentation, share a common regulatory pathway defective in BLS. 
T 
ype II bare lymphocyte syndrome (BLS) or HLA class 
II-ddicient combined immunodeficiency  is an autosomal 
recessive disorder in which HLA class II structural genes are 
not transcribed due to a mutation in a gene encoded outside 
of the MHC (1). This lack of HLA class II expression com- 
promises patient immunity, leading to recurrent bacterial and 
viral infections. Several lines of evidence suggest that the BLS 
phenotype results from a defect in a trans-acting  factor neces- 
sary for transcription of the coordinately regulated class II 
genes (reviewed in reference 2). 
Clustering of genes for histocompatibility antigens and ac- 
cessory molecules required for antigen presentation may en- 
sure the coordinate expression and function of these molecules. 
The HLA class I and class II structural genes on chromo- 
some 6 are interspersed with genes necessary for antigen re- 
sponsiveness (3). The ability of class I molecules to present 
antigens is dependent upon functional transporters associated 
with antigen processing (TAP) genes which are required to 
supply peptides to class I molecules in the endoplasmic retic- 
ulum (reviewed in reference 3). The TAP genes map between 
the HLA-DQ and -DP structural genes; in addition to this 
genetic proximity, they are coregulated with class Iot struc- 
tural genes by IFN-7 (3). Similarly, genes essential for ap- 
propriate class II-mediated antigen presentation map within 
this same region of the MHC (4, 5). Transcriptional regula- 
tion of genes encoded outside the MHC may also be coordi- 
nated with histocompatibility antigens to facilitate immune 
function. Class II antigens and their intraceUular chaperone, 
the invariant chain, are upregulated in response to IFN-3' (6). 
Whether transcriptional elements are shared by additional 
genes required for class tI-restricted antigen presentation has 
not been addressed. 
Restoration of cellular immune responses in BLS is depen- 
dent upon the expression of functional HLA class II antigens 
in these patients. To determine whether stable transfection 
of dass II DR c~ and ~ subunits would restore immunocom- 
petency in BLS, studies of class II antigen structure and func- 
tion were initiated using BLS-1, an immortalized B cell line 
derived from a BLS patient (7). BLS-1 cells expressing abun- 
dant amounts of cell surface DR4w4 or DR5 molecules were 
unable to present exogenous antigens to T lymphocytes. In 
addition, conformationally altered class II c~fl complexes were 
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the HLA alldes, DR3 or DR4w4.  Complementation anal- 
),sis indicated that a trans-acting  factor was necessary to re- 
store a wild-type APC phenotype to BLS-1 calls.  Our data 
suggest  that the mutated gene that controls class II struc- 
tural gene transcription  also regulates the expression of gene(s) 
controlling  class  II-mediated  antigen presentation. 
Materiah  and Methods 
Cell Lines.  Class  II DRot (DRA1) and DP~  (DtLBI"0401, 
DtLBl*1101,  DRBI'0301) cDNA encoding DR4w4,  DR5w11, 
and DR3w17 molecules were introduced into BLS-1 using retrovi- 
ms-mediated gene transfer (8). T2 (.174 xCEM.T2) is a human cell 
hybrid that lacks all four copies of the MHC class II region on 
chromosome 6 (9). T2.DR4w4 (provided by W. Kwok, Virginia 
Mason Research Center, Seattle, WA) and T2.DR3 and T1.DR3 
(10) were generated by transfer of the DRA1 and DRBI*0401 or 
DRBI"0301  genes.  T1 is the progenitor of T2 and retains  one 
unmutated copy of chromosome 6. Cell lines were grown in IMDM 
plus 10% FCS. 
Assays with T Cell Clones.  The anti-HAR and BCHA59 human 
T cell clones (provided by  J. Krieger and A. Sette, Cytel, San Diego, 
CA) were isolated by limiting dilution cloning after stimulation 
of DR5 or DR4w4 PBL with HA 307-319 (11). To measure T 
cell proliferation, APCs (3  x  104) were pulsed for 3 h with fixed 
A/Mississippi/I/85 (H3N2) virus (Connaught Laboratories, Swift- 
water, PA) or HA 307-319 peptide (PKYVKQNTLKLAT), washed, 
irradiated, plated in microwells with an equal number of T cells, 
and incubated for 72 h, with [3H]thymidine (1/~Ci/well) present 
during  the  last  15  h.  Live A/Bangkok/1/79  virus  (200-300 
HAU/ml) (provided by P. Cresswell, Yale University, New Haven, 
CT) was incubated with cells in serum free medium for 1 h at 
37~  to allow viral adherence; nonadherent virus was washed away 
and cells were resuspended in complete medium for 24 h before 
incubation with T  cells. 
Assays with T Cell Hybridomas.  The DR4w4-tetanus-specific 
T cell hybridoma 49.23.2 was generated after tetanus immuniza- 
tion of a DR4w4  transgenic mouse (12) as described (13). For- 
malin fixed tetanus toxoid (TT) (Wyeth Laboratories, Philadelphia, 
PA) was digested with N-tosyl-L-phenylalanine chloromethyl ke- 
tone (TPCK) trypsin. APC (10s), TT antigen (native or trypsin 
digested) (0.4/~M) and 49.23.2 T  cells (10  s) were incubated to- 
gether for 24 h. T cell IL-2 and IL-4 production was determined 
by the survival of an Ib2/K,4-dependent cell line, HT-2, measured 
using 3-[4,5-dimethylthiazol-2-y]-2,5-diphenyltetrazolium  bromide 
(MTT) (14). The presence of antigenic peptides in the tryptic di- 
gest of TT was confirmed by incubating the digested preparation 
with fixed APCs.  The T  cell hybridoma did not produce lym- 
phokines in response to APC's in the absence of antigen. 
Antibody Binding Assays.  For flow cytometry experiments, the 
anti-DR mAb L243 (15) and the anti-DR3 mAb 16.23 (16) were 
used at saturating concentrations and binding was detected with 
FITC-conjugated goat anti-mouse Ig using a FACScan  |  (Becton 
Dickinson & Co., Mountain View, CA). Binding of anti-DR4w4 
mAbs was detected with a live cell enzyme-linked immunoassay 
(CELISA)  (17). 
CellF~io~.  Fusions between BLS-1 (DR3,5) and SJO (DR5, 
7) ceils were carried out using 50% polyethylene glycol-1500, 5% 
DMSO (18). Before ceil hybridization, bygromycin-resistance or 
neomycin genes were introduced into BLS-1 or SJO, respectively; 
the fused cells were selected for using hygromycin B (150/~g/ml) 
and G418 (1 mg/ml). Four independently fused drug-resistant  popu- 
lations were analyzed for cell surface expression of the endogenous 
DR molecules. 
Results  and  Discussion 
BLS-1 cells e~pressing high levels of call surface DR mole- 
cules were assessed  for their ability to process and present 
foreign protein antigens to T  cells.  The BLS-1.DR5 trans- 
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Figure  1.  BLS-1.DR  transferents  are unable to mediate  class H-restricted 
presentation of exogenous  native protein antigens to T ceUs. (,4) Respome 
of the anti-HAR T cell clone to the DR5 B cell line Sweig (solid Mrs) 
and BLS-I.DR5 cells (open bars) after incubation with 45 #g/mi formalin- 
fixed A/Mississippi influenza virus (fixed flu), infection with llve A/ 
Bangkok influenza virus (inf. flu), or incubation with 1/zg/ml peptide 
HA 307-319. (/3) Proliferation of T cell clone BCHA59 to the DR4w4 
B ceU line  JAH (solid bars) and BLS-1.DK4w4  (open bars) cells after incuba- 
tion with HA 30%319 or fixed A/Mississippi influenza virus. Two con- 
centrations of  influenza  virus were used: flu1, 45 #g/ml; flu 2, 180 #g/m1. 
T cell proliferation data presented are mean values of [3H]thymidine  in- 
corporation from triplicate cultures of representative experiments; stan- 
dard deviation  of the means was <15%. cpm values  resulting from prolifer- 
ation of T calls in response to APCs in the absence of antigen have been 
subtracted. (C) Lymphokine  production  (IL-2  and II..4) by T cell  hybridoma 
49.23.2 in response to the DK4w4 B cell line priess (solid bars), BLS- 
1.DK4w4 (open bars), or T2.DK4w4 (hatched  bars) after incubation with 
0.4/zM native tetanus toxoid protein or a tryptic digest of TT peptides. 
Data are representative of four experiments. 
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equally well to a DRS/HA 307-319-restricted  T cell clone 
(Fig. 1A). In contrast, BLS-1.DR5 incubated with formalin- 
fixed influenza virus did not stimulate proliferation  of the 
T cell clone (Fig. 1 A), suggesting that BLS-1.DR5 was un- 
able to mediate presentation of native HA. TO increase the 
amount of intracellular influenza HA, APCs were infected 
with live influenza virus before T  cell addition;  the T cell 
clone proliferated in response to the influenza-infected DR5 
B cell line, yet there was no response to vitally infected BLS- 
1.DR5 (Fig. 1 A). Similarly, a BLS-1.DR4w4 transferent was 
unable to stimulate proliferation of a DR4w4/HA 307-319 
restricted T cell done after incubation with native influenza 
virus proteins, whereas the presentation of the HA 307-319 
peptide by  BLS-1.DR4w4  was  comparable  to  that  of a 
homozygous DR4w4 B cell line (Fig.  1 B). 
The defect in exogenous antigen presentation  by BLS-1 
was also observed with another native antigen, TT. Upon 
incubation with native TT, BLS-1.DR4w4  was ineffective 
in stimulating a murine T cell hybridoma that is spedfic for 
tetanus presented in the context of DR4w4 (Fig. 1 C). T 
cell responses to BLS-1.DR4w4  and tetanus were reduced 
10-fold when compared with a bomozygous DR4w4 B cell 
line. Incubation of these APCs with proteolyzed TT (con- 
taining antigenic peptides) resulted in activation of the T cell 
hybridoma (Fig.  1 C).  Thus,  BLS-1 cells expressing  two 
different DR alleles, DR4w4 or DR5, were unable to mediate 
class II-restricted antigen presentation to antigen-specific T 
cells after incubation with the native protein antigens, TT 
and influenza HA; however, BLS-1.DR transferents could 
present preprocessed antigenic peptides derived from these 
proteins as efficiently as wild-type B cell lines. The inability 
of BLS-1 cells to present native protein antigens was not due 
to a defect in internalization  of exogenous antigens.  Infec- 
tion of BLS-1 with influenza did not facilitate presentation 
of the viral HA antigen (Fig. 1 A). In addition, BLS-1 and 
the wild-type B cell lines were equally able to internalize TT 
or influenza virus present in the culture medium (data not 
shown). 
This defect in class II-mediated antigen presention is similar 
to the phenotype of the in vitro generated mutant cell lines 
9.5.3 (19), 721.174 (5), and the related cell T2 (10). These 
mutant cell lines each lack a gene required for the processing 
and presentation of native exogenous class II-restricted an- 
tigens.  A  comparison  of BLS-1.DR4w4  and the mutant 
T2.DR4w4 indicated that the ability of each of these cells 
to present TT to T cells was similarly reduced (Fig. 1 C). 
The mutation in 721.174 and 9.5.3 maps between the LMP2 
and DNA genes in the class II region of the HLA gene com- 
plex (4,  5). 
A characteristic feature of the in vitro-generated mutant 
APC is the expression of structurally aberrant  class II od3 
dimers lacking specific  epitopes (5, 19). To assess the confor- 
mation of the DR molecules present on the surface of BLS- 
1.DR transferents, BLS-1.DR3 and BLS-1.DR4w4 cells were 
analyzed  for binding of allele-specific,  conformation-dependent 
anti-DR3 and anti-DR4w4 mAbs using flow cytometry  and 
CELISA  (Fig. 2).  The  mAb  16.23, which recognizes  a 
conformation-dependent epitope on DR3 molecules, binds 
to DR3 molecules on wild-type DR3 cell lines but not on 
BLS-1.DR3 or mutant T2.DR3 cells (Fig. 2 A). Expression 
of the epitope bound by another anti-DR mAb, L243 is 
unaffected by the mutations in these cells. 
A panel of anti-DR4w4-specific mAbs (20, 21) was used 
to probe the structure of DR4w4 on BLS-1.DR4w4  cells 
and a DR4w4 homozygous B cell line (Fig. 2 B). Two of 
these mAbs, NFLD.D1  and NFLD.D10,  bound to DR4w4 
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Figure 2.  Binding of allele-specific,  confor- 
marion dependent anti-DIL3 and anti-DR4w4 
mAbs to BLS-1.DR transferents  is greatly re- 
duced. (,4) Binding of the anti-DR3 mAb 16.23 
(dotted line), mAb L243 (flick line) and an ir- 
relevant mAb NN4 (thin line) to the DR3 trans- 
ferent cell lines T1.DR3, T2.DR3, and BLS- 
1.DR3. Fluorescence intensity was determined 
after binding of mAbs and flow cytometry. (B) 
Binding of a panel of anti-DR4w4 mAbs and 
mAb L243 to the DR4w4 B cell line WT51 
(hatched Mrs) and BLS-1.DR4w4 (solid Mrs). 
Binding was detected using a live CELl&&. The 
absorbance (OD 490 am) resulting from incu- 
bation of cells with medium alone has been sub- 
tracted. 
2019  Kovats et al.  Brief Definitive Report mAb L243.  However,  mAbs NFLD.Dll  and  NFLD.D12 
bound wild-type DR4w4 B cells  but not BLS-1.DR4w4 cells; 
these mAbs had previously been shown to bind epitopes that 
are dependent on DR4w4-peptide complexes and do not bind 
to the DR4w4 molecules  on the surface  of  mutant T2.DR4w4 
cells (20). Binding ofmAb NFLD.D2, which also recognizes 
an epitope dependent on dass II conformation, was reduced 
on BLS-1.DR4w4 cells. Taken together, these data with both 
anti-DR4w4 and anti-DR3 mAb suggest that the DR mol- 
ecules on the surface of BLS-1 cells are structurally altered 
and thus do not display epitopes recognized by conforma- 
tionally sensitive antibodies. This defect in class II antigen 
structure has been linked with the impaired ability of mu- 
tant cells to present peptides derived from exogenously added 
proteins. 
Surface expression of endogenous dass II DR, DOo and 
DP molecules is restored upon fusion of B cell lines isolated 
from different BLS patients, indicating that the defect in class 
II gene transcription differs  among BLS cell lines and allowing 
the definition of four genetic complementation groups (18). 
BLS-1 is a member of complementation group I. SJO, a B 
cell line derived from a patient in complementation group 
IV (22), was transfected with genes encoding DR4w4 mole- 
cules and found to display a mutant APC phenotype iden- 
tical to that of BLS-1.DR4w4  (data not shown). To deter- 
mine if the defects in antigen presentation in BLS-1 and SJO 
could be complemented  by trans-acting factors present in each 
cell line, BLS-1 was fused with SJO. BLS-1  x  SJO hybrids 
were isolated and screened  for wild-type DR3 expression  using 
mAb 16.23. The hybrid cells were found to express the en- 
dogenous DR3 molecule from BLS-1 with a wild-type con- 
formation (Fig. 3), indicating that a tram-acting factor present 
in SJO can restore the production of  functional dass II mole- 
cules and therefore the ability to present exogenous antigens. 
Our results demonstrate that BLS-1.DR  transferent cells 
have a defect in the dass II-mediated presentation of native 
exogenous protein antigens to T cells. The dass II o~3 dimers 
formed in these cells also fail to express conserved epitopes 
as detected by conformationally sensitive antibodies. BLS-1, 
a cell deficient in the transcription of class II structural genes, 
is therefore remarkably similar in phenotype to a set of in 
vitro-generated APC mutants. Genetic studies indicate that 
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Figure 3.  Fusion of class II- 
negative  BLS-1 and  SJO  cells 
results in expression of wild-type 
endogenous DR3 molecules that 
bind  mAb  16.23. Binding  of 
anti-DR  mAb  L243 (.4)  and 
anti-DR3  mAb  16.23 (B)  to 
BLS-1 (thick line),  SJO (thin line), 
BLS-1 x SJO fusion 1 (thick dotted 
line)  and BLS-1 x  SJO fusion 2 
(thin dotted line).  Fluorescence in- 
tensity  was  determined  after 
binding  of  mAbs  and  flow 
cytometry. 
the mutations in these two classes of cells, one a regulatory 
mutant and the other a structural gene defect, map to different 
locations in the genome (4,  5,  18). 
Complementation of endogenous class II gene expression, 
as well as the defect in antigen presentation,  was observed 
upon fusion of two different BLS cell lines. Since neither BLS 
cell line is able to mediate presentation of e~ogenous antigens, 
the mutations resulting in an impaired APC phenotype are 
different in BLS-1 and SJO. Coregulation of class II struc- 
tural genes and the gene(s) controlling antigen presentation 
at a transcriptional level  would best explain these results. Thus, 
the two phenotypic defects in BLS cells are likely to arise 
as a result of mutations in a single trans-acting gene. Alterna- 
tively, the two phenotypic defects in BLS cells may be due 
to mutations in two separate genes that independently regu- 
late class II structural gene transcription  and transcription 
of genes required for antigen presentation.  This latter possi- 
bility seems unlikely, however, since BLS is due to sponta- 
neous mutations. 
Genomic in vivo footprinting studies in BLS cell lines have 
shown that the promoters of class II DR and DQ genes in 
complementation groups  I, III,  and IV are unoccupied by 
protein factors that normally bind at multiple c/s-acting  DNA 
consensus elements (23). The "bare" promoters could result 
from the absence of a promoter binding protein that is crit- 
ical for binding of other regulatory proteins  to all dass II 
structural gene promoters; alternatively, bare promoters may 
be due to a local defect in chromatin structure in the MHC 
class II region that renders the promoters of class II genes 
inaccessible to any factor binding (24). We assessed whether 
the class II region of the MHC was globally inactivated by 
monitoring transcription  of several genes within the MHC 
including the TAP1, TAP2, and RING1 genes. The TAP genes 
(3) map between DOB and LMP2 near the putative  gene 
controlling antigen presentation  and the RING1 gene (25) 
maps centromeric to DPB2. Northern blotting and PCR anal- 
yses showed that TAP1, TAP2, and RING1 mRNA is present 
in BLS-1 (data not shown), indicating that the promoters 
of these genes reside in chromatin that is accessible to tran- 
scription factors; similar results with the LMP2 and LMP7 
genes have been obtained with SJO (22). However, SJO does 
not express the DMA and DMB genes which encode a class 
II-like molecule and map between LMP2 and DNA (22); 
the DMA and DMB genes contain promoter regions that 
are similar to the promoters of the class II DR, DO~ and 
DP structural genes (26) and thus may be jointly regulated. 
Regulatory protein(s) defective in BLS cell lines may con- 
trol the accessibility of class II promoters within their native 
chromosomal environment (24). Since we found that the mu- 
tation(s) in BLS-1 influence a gene or genes that regulate both 
HLA dass II gene expression and function, this implies a 
level of transcriptional  coregulation,  perhaps with the pro- 
moter region 5' of the antigen presentation genes containing 
the same c/s-acting consensus sequences (X, Y, and W boxes) 
or locus control region that are upstream of each of the class 
2020  Deficient Antigen Presentation in Bare Lymphocyte Syndrome Cells II structural genes. To fully restore immune responsiveness 
in BLS patients, immunotherapeutic approaches must there- 
fore be based on restoration of transcription factors or the 
expression  of both class II structural genes and genes con- 
trolling antigen presentation. 
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